I voted no on the split. Ask me next year after the Phase II results, and validation of the platform, and I'll vote yes. It is too early to be asking shareholders about reverse split in my opinion. If the clinical results are good, we should be above $10 in no time. Yes, it'll be less volatile, but there is nothing wrong with volatility if your clinical results are great. Don't put the cart before the carrot.
Voted Yes. At these levels INO doesn't get the respect that it deserves. Even after Phase 2 results turn to be positive, it would still be a less than $10 stock. INO needs to get into the high 10's and 20's. This will definitely decrease the amount of volatility we currently see.
My overall account value won't decrease/increase if I have 200 or 2000 shares. I'm long and I'm confident that with a higher PPS, and good results, INO will be a $30+ stock a year from now.